Pharmaceutical composition comprising prmt5 inhibitor and EGFR inhibitor

HK40137425APending Publication Date: 2026-09-11SHANGHAI APEIRON THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125265
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-04
Filing Date
2026-06-25
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed is a pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and an epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor. The pharmaceutical composition can be used for treating various cancers, including solid tumors. The combination can be used for treating any number of diseases related to PRMT5 and / or EGFR.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202580003272.3 (22) Application Date 2025.01.24 (66) Domestic Priority Data 202410116672.2 2024.01.26 CN 202410245514.7 2024.03.04 CN (85) PCT International Application Entering National Phase Date 2025.12.18 (86) PCT International Application Application Data PCT / CN2025 / 074945 2025.01.24 (87) PCT International Application Publication Data WO2025 / 157287 ZH 2025.07.31 (71) Applicant Shanghai Pailong Biotechnology Co., Ltd. Address 201210 Pudong New Area, Shanghai, China (Shanghai) Room C101, Building 1, No. 1976, Gaoke Middle Road, Free Trade Zone (72) Inventors: Mao Weifeng, Yao Bing, Fred Julian Aswad, Li Mingxi, Gu Xiaohui, James David Joseph (74) Patent Agency: Beijing Shengran Weian Intellectual Property Agency (General Partnership) 16297 Patent Attorney: Wang Hong (51) Int.Cl. A61K 45 / 06 (2006.01) A61K 31 / 536 (2006.01) A61K 31 / 519 (2006.01) A61P 35 / 00 (2006.01) A61K 31 / 501 (2006.01) A61K 31 / 4985 (2006.01) (54) Pharmaceutical Composition with Title Containing PRMT5 Inhibitor and EGFR Inhibitor (57) Abstract discloses a pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and an epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor. This pharmaceutical composition can be used to treat a variety of cancers, including solid tumors. This combination product can be used to treat any number of diseases associated with PRMT5 and / or EGFR. CN 121398850 A 2026.01.23 CN 1 21 39 88 50 A